Ceruletide
A cholecystokinin mimic for the gut and pancreas
Ceruletide, also called caerulein, is a peptide analogue of cholecystokinin. It contracts the gallbladder, stimulates the pancreas and speeds the gut, and was marketed in the US as Tymtran for diagnostic tests. It is now discontinued there, and is best known as the standard laboratory tool for inducing pancreatitis in animals.
Used in human trials: 2.5 ng/kg/min, Single infusion, Intravenous (Trial: ileus after abdominal surgery) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Work out syringe units → · New to syringes? · All dosing data ↓
What is it?
Ceruletide shares its active end with cholecystokinin, the gut hormone that empties the gallbladder and drives pancreatic enzyme secretion. A 1982 pharmacology review described its uses: as an aid to small-bowel X-rays, for treating postoperative ileus and intestinal atony, and for testing exocrine pancreatic function. Its side effects at therapeutic doses were mild, transient extensions of its actions, such as nausea, vomiting, abdominal pain and, rarely, low blood pressure and fast heart rate. Controlled trials backed two of those uses: after abdominal surgery an infusion restarted bowel activity sooner than placebo, and in biliary colic an injection eased pain about as well as pentazocine, though not in kidney-stone colic. In healthy volunteers its effect on pain depended on the kind of pain tested.
Its diagnostic use rested on the gallbladder. Given by injection, ceruletide contracted the gallbladder within 30 minutes, more than a fatty meal did in one comparison, and during biliary colic it relieved pain while lowering sphincter of Oddi pressure. It did not work as a pancreatic function test through amino acid changes, which could not separate healthy people from patients.
In the 1980s it was tried in psychiatry, because cholecystokinin analogues showed neuroleptic-like activity in mice. A double-blind trial in 17 people with chronic schizophrenia found few differences from placebo, with exceptions as likely to favour placebo. In 37 people with tardive dyskinesia, ceruletide's effect did not differ significantly from placebo overall, though it did better in those under 60.
Research in the 1990s used it to probe cholecystokinin's effects on the human brain. Intravenous ceruletide increased EEG markers of selective attention and cognitive processing in young adults but not in the elderly, reduced memory for food pictures in fasting men as a meal does, and released ACTH within minutes.
Today its main use is in research. Caerulein is used to injure pancreatic cells as a model of acute pancreatitis; a 2024 study, for example, used caerulein-stimulated human pancreatic duct cells alongside blood from patients. In the US the medicine is discontinued, and Drugs@FDA lists no current product. A 2025 study showed cerulein directly excites human visceral sensory neurons through the CCK-A receptor, a link to pancreatitis pain.
Mechanism of Action
Ceruletide (caerulein) is a peptide that shares cholecystokinin's active end and acts on CCK receptors.
Gallbladder contraction
It contracts the gallbladder within 30 minutes, the basis of its diagnostic use.
Gut motility and pancreas
It restarted bowel activity after surgery and drives pancreatic secretion; it is used to injure the pancreas in pancreatitis models.
Brain and pain
In people it changed EEG markers of attention and released ACTH; it excites visceral pain neurons through CCK-A.
Published Research
Studies of ceruletide, from their PubMed abstracts.
Ileus after abdominal surgery
In a double-blind trial of 91 patients, a one-hour ceruletide infusion after elective abdominal surgery brought audible bowel sounds in 42 of 47 against 30 of 44 on placebo, and more passed flatus by day 2-3 (22 of 45 against 9 of 44), at the cost of more short-lived nausea and vomiting.
Biliary and renal colic against pentazocine
In a randomised double-blind study of 82 patients, intramuscular ceruletide (0.5 µg/kg) relieved biliary colic about as well as pentazocine with fewer side effects, but was significantly worse than pentazocine for renal colic.
Experimental pain in healthy men
In a placebo-controlled crossover study in 25 healthy men, ceruletide raised the threshold for thermal pain at both doses, left ischaemic pain unchanged, and at the higher dose lowered tolerance for mechanical pain.
Gallbladder emptying on ultrasound
In 55 gallstone patients given intramuscular ceruletide 0.3 µg/kg, maximal gallbladder contraction at 30 minutes was 47.5% against 33.9% with a fatty-meal X-ray test, with acceptable day-to-day variation and minor, self-limiting side effects.
During biliary colic
In 10 gallstone patients, the gallbladder was eight times larger during colic than after it, and caerulein relieved the colic pain in every case while shrinking the gallbladder and lowering sphincter of Oddi pressure.
Not a pancreatic function test
Plasma amino acid falls after cerulein were small, showed no dose response and could not separate volunteers from patients with pancreatic insufficiency, while pancreatic polypeptide rose dose-dependently.
Selective attention
In a double-blind crossover study in healthy people, intravenous ceruletide, most clearly at 2.5 µg, increased an EEG marker of selective attention against placebo.
Young versus elderly brains
In 16 young and 16 elderly volunteers, a 30-minute ceruletide infusion enhanced cognitive EEG markers in the young but had no effect in the elderly.
Satiety and memory
In fasting men, intravenous ceruletide reduced recognition of food pictures much as a meal did, suggesting it mimics satiety's effect on memory.
ACTH release
In men, ceruletide infusion released ACTH within minutes; loperamide blunted the peak, and naloxone reversed that blunting.
Pharmacology, uses and adverse effects
Ceruletide stimulates gallbladder contraction, pancreatic secretion and intestinal motility; it was used diagnostically for small-bowel X-rays and pancreatic function, and therapeutically for postoperative ileus, with mild, transient side effects such as nausea, vomiting and abdominal pain.
Schizophrenia: double-blind trial
In 17 people with chronic schizophrenia continuing neuroleptics, two ceruletide injections produced few significant differences from placebo, with exceptions as likely to favour placebo, and no predictors of benefit.
Tardive dyskinesia
In 37 patients, weekly ceruletide for 4 weeks did not differ significantly from placebo overall, but was more effective in patients under 60 and those mainly on butyrophenones; no serious side effects occurred.
Gallbladder emptying across species
Ceruletide infusion emptied the gallbladder almost completely in rabbits (85% ejection fraction) but left more residual bile in prairie dogs, which the authors linked to the prairie dog's tendency to form gallstones.
Caerulein as a pancreatitis model
Researchers used caerulein-stimulated human pancreatic duct cells as a model of acute pancreatitis, finding that the enzyme DUOX2 was raised in patients' blood and that a microRNA affected caerulein-induced duct cell injury and pyroptosis.
Visceral pain neurons
Cerulein made mouse and human visceral sensory neurons more excitable through the CCK-A receptor, and mice injected with it developed pain behaviours.
Dosing Data
Ceruletide is discontinued in the US. Published human studies used weight-based injections or short infusions.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Ceruletide is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intramuscular, intravenous). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.
Source: the route and amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Ceruletide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Ceruletide stays intact once mixed.
How it is taken
As it was given in human studies: Intravenous (Single infusion; Trial: ileus after abdominal surgery); Intramuscular (Single dose; Study: gallbladder emptying test).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: ileus after abdominal surgery: 1 hour; Study: gallbladder emptying test: One test.
When effects appear: unknown; no source on this page gives a time to effect for Ceruletide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Nausea, vomiting and abdominal pain; Rarely low blood pressure and fast heart rate. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Ceruletide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Ceruletide (reviewed 2026-10-05) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Ceruletide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Marketed in the US as Tymtran (ceruletide diethylamine), NDA 018296). Sport: Unsettled (S0 may apply).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No current US label: the product is discontinued and DailyMed has no label (read October 3, 2026).
Legal Status
Ceruletide is no longer marketed in the US.
Frequently Asked Questions
?Is ceruletide the same as caerulein?
Yes. Caerulein (or cerulein) is the name used in laboratory research; ceruletide is its drug name.
?Why is caerulein used in pancreatitis research?
It injures pancreatic cells in a way that mimics acute pancreatitis, so researchers use it to model the disease in cells and animals.
?Did ceruletide help schizophrenia?
No. A double-blind trial found few differences from placebo, after earlier open studies had suggested benefit.
?What side effects did ceruletide cause?
The 1982 review described them as mild, transient extensions of its actions: nausea, vomiting and abdominal pain, and rarely low blood pressure and a fast heart rate. The tardive dyskinesia trial reported no serious side effects.
?How was ceruletide used to test the gallbladder?
A single intramuscular dose of 0.3 µg/kg contracted the gallbladder within 30 minutes, measured by ultrasound; contraction was greater than with a fatty-meal X-ray test.
?Does it affect the brain?
In 1990s volunteer studies, intravenous ceruletide increased EEG markers of attention in young adults, not the elderly, and released ACTH within minutes.
References
- [fda] US FDA, Drugs@FDA (openFDA): TYMTRAN, NDA 018296, marketing status discontinued; no label on DailyMed. Read October 3, 2026.
- [pubmed] Vincent ME, et al. "Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent." Pharmacotherapy, 1982;2(4):223-34. PMID: 6763205.
- [clinical-trial] Mattes JA, et al. "Ceruletide for schizophrenia: a double-blind study." Biol Psychiatry, 1985;20(5):533-8. PMID: 2859054.
- [clinical-trial] Matsunaga T, et al. "The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study." Prog Neuropsychopharmacol Biol Psychiatry, 1988;12(4):533-9. PMID: 3043555.
- [pubmed] Krishnamurthy GT, et al. "Gallbladder filling and post-ceruletide emptying in prairie dogs and rabbits." Nucl Med Commun, 1988;9(5):382-8. PMID: 3412728.
- [pubmed] Zhang G, et al. "miR-605-3p may affect caerulein-induced ductal cell injury and pyroptosis in acute pancreatitis by targeting the DUOX2/NLRP3/NF-κB pathway." PeerJ, 2024;12:e17874. PMID: 39224819.
- [clinical-trial] Sadek SA, et al. "Pharmacological manipulation of adynamic ileus: controlled randomized double-blind study of ceruletide on intestinal motor activity after elective abdominal surgery." Aliment Pharmacol Ther, 1988;2(1):47-54. PMID: 2979233.
- [clinical-trial] Lishner M, et al. "Analgesic effect of ceruletide compared with pentazocine in biliary and renal colic: a prospective, controlled, double-blind study." Drug Intell Clin Pharm, 1985;19(6):433-6. PMID: 3891284.
- [clinical-trial] Pause BM, et al. "Analgesic effect of ceruletide in men is limited to specific pain qualities." Physiol Behav, 1996;59(6):1025-31. PMID: 8737889.
- [pubmed] Muraca M, et al. "Ultrasonic evaluation of gallbladder emptying with ceruletide: comparison to oral cholecystography with fatty meal." Abdom Imaging, 1994;19(3):235-8. PMID: 8019351.
- [pubmed] Pizzuto G, et al. "[Echographic and ERCP-manometric study of gallbladder and Oddi's sphincter behavior in biliary colic in patients with cholelithiasis. Effects of cerulein]." Minerva Chir, 1996;51(12):1145-9. PMID: 9064590.
- [pubmed] Borovicka J, et al. "Cerulein-induced changes in plasma amino acid concentrations are not a valid test for pancreatic insufficiency." Am J Gastroenterol, 1995;90(7):1111-5. PMID: 7611207.
- [pubmed] Schreiber H, et al. "Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons." Biol Psychiatry, 1995;37(10):702-12. PMID: 7640325.
- [pubmed] Dodt C, et al. "Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans." J Clin Psychopharmacol, 1996;16(6):440-5. PMID: 8959469.
- [pubmed] Pietrowsky R, et al. "Comparison of satiating effects of ceruletide and food intake using behavioral and electrophysiological indicators of memory." Int J Psychophysiol, 1994;17(1):79-89. PMID: 7961057.
- [pubmed] Auernhammer CJ, et al. "In man the mu-opiate agonist loperamide specifically inhibits ACTH secretion induced by the cholecystokinin-like peptide ceruletide." Neuroendocrinology, 1994;60(1):16-22. PMID: 8090278.
- [pubmed] Goyal S, et al. "Visceral pain-related acute actions of cerulein on mouse and human sensory neurons." Mol Pain, 2025;21:17448069251353346. PMID: 40524328.
Sources & Citations
Studies were read from their PubMed abstracts; a 1996 duplicate report of the gallbladder study was not cited separately. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.